J 2021

Both Hypoxia-Inducible Factor 1 and MAPK Signaling Pathway Attenuate PI3K/AKT via Suppression of Reactive Oxygen Species in Human Pluripotent Stem Cells

FOJTÍK, Petr, Deborah BECKEROVÁ, Kateřina HOLOMKOVÁ, Martin ŠENFLUK, Vladimír ROTREKL et. al.

Basic information

Original name

Both Hypoxia-Inducible Factor 1 and MAPK Signaling Pathway Attenuate PI3K/AKT via Suppression of Reactive Oxygen Species in Human Pluripotent Stem Cells

Authors

FOJTÍK, Petr (203 Czech Republic, belonging to the institution), Deborah BECKEROVÁ (203 Czech Republic, belonging to the institution), Kateřina HOLOMKOVÁ (203 Czech Republic, belonging to the institution), Martin ŠENFLUK (203 Czech Republic, belonging to the institution) and Vladimír ROTREKL (203 Czech Republic, guarantor, belonging to the institution)

Edition

Frontiers in Cell and Developmental Biology, Lausanne, Frontiers Media S.A. 2021, 2296-634X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10605 Developmental biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 6.081

RIV identification code

RIV/00216224:14110/21:00120104

Organization unit

Faculty of Medicine

UT WoS

000614417600001

Keywords in English

PI3K; AKT; MAPK; reactive oxygen species; hPSCs; HIF-1; hypoxia

Tags

Tags

International impact, Reviewed
Změněno: 21/2/2022 12:47, Mgr. Tereza Miškechová

Abstract

V originále

Mild hypoxia (5% O-2) as well as FGFR1-induced activation of phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/AKT) and MAPK signaling pathways markedly support pluripotency in human pluripotent stem cells (hPSCs). This study demonstrates that the pluripotency-promoting PI3K/AKT signaling pathway is surprisingly attenuated in mild hypoxia compared to the 21% O-2 environment. Hypoxia is known to be associated with lower levels of reactive oxygen species (ROS), which are recognized as intracellular second messengers capable of upregulating the PI3K/AKT signaling pathway. Our data denote that ROS downregulation results in pluripotency upregulation and PI3K/AKT attenuation in a hypoxia-inducible factor 1 (HIF-1)-dependent manner in hPSCs. Using specific MAPK inhibitors, we show that the MAPK pathway also downregulates ROS and therefore attenuates the PI3K/AKT signaling-this represents a novel interaction between these signaling pathways. This inhibition of ROS initiated by MEK1/2-ERK1/2 may serve as a negative feedback loop from the MAPK pathway toward FGFR1 and PI3K/AKT activation. We further describe the molecular mechanism resulting in PI3K/AKT upregulation in hPSCs-ROS inhibit the PI3K's primary antagonist PTEN and upregulate FGFR1 phosphorylation. These novel regulatory circuits utilizing ROS as second messengers may contribute to the development of enhanced cultivation and differentiation protocols for hPSCs. Since the PI3K/AKT pathway often undergoes an oncogenic transformation, our data could also provide new insights into the regulation of cancer stem cell signaling.

Links

MUNI/A/1325/2020, interní kód MU
Name: Biomedicínské vědy
Investor: Masaryk University
NU20-06-00156, research and development project
Name: Vliv pneumologické medikace na funkce lidských kardiomyocytů.
Investor: Ministry of Health of the CR, Subprogram 1 - standard